We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Eli Lilly (NYSE:LLY) is taking the unusual step of asking people who took compounded versions of their drug tirzepatide, ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Shutterstock / Caroline Ruda In 2022, the FDA placed tirzepatide — the active ingredient in Eli Lilly’s Mounjaro and Zepbound ...

Novo Nordisk has reaped large rewards from its status as a frontrunner ... Meanwhile, Lilly’s 2023 revenue exceeded $34 ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new trials ...